ATEZOLIZUMAB - BEVACIZUMAB in the Treatment Hepatocellular Carcinoma Inoperable or
- Conditions
- Advanced Hepatocellular Carcinoma
- Registration Number
- NCT04730388
- Lead Sponsor
- University Hospital, Brest
- Brief Summary
Evaluation of the efficacy and safety of the combination ATEZOLIZUMAB - BEVACIZUMAB in the treatment of locally advanced inoperable or metastatic hepatocellular carcinoma in Finistère
- Detailed Description
Patients treated by ATEZOLIZUMAB and BEVACIZUMAB for an Advanced hepatocellular carcinoma will be followed to observed their safety and the efficacy of this treatment, and to identify prongnosis factors
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- hepatocellular carcinoma locally advanced or metastatic, non able to be resectable, with no prior systemic treatment
- Child Pugh A and ECOG 0 or 1
- upper digestiuve endoscopy less than 6 months, if esophageal varcices : must be treated
- non eligible to receive a locoregional therpay or progressive after this kinf of treatment
- with informed consent
Exclusion Criteria
- refuse to participate
- under legal protection
- exclusion criteria from the tempory utilisation authorization
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method predictive factor for progression-free survival 12 months progression-free survival = time between treatment initiation and rediologic or clinical progression
- Secondary Outcome Measures
Name Time Method